How the C-suite sees AI, what’s next for CRISPR and why health tech needs better marketing

On the show today, the Food and Drug Administration expanded its approval for CRISPR gene-editing therapies. We look at the affordability of these treatments, which can cost well into the millions of dollars. Plus, is bad marketing stunting health tech companies? More on how startups can up their game. But first, at this week’s World Economic Forum in Davos, Switzerland, there were 32 scheduled events devoted to AI. When they weren’t comparing private jets, business executives were busy asking, “How do you make money off AI?” Marketplaces’ Lily Jamali is joined by Christina Farr, a health tech investor at OMERS Ventures, for her take on these stories.